---
annotation-target: bloodadvances.2022008292.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-15T02:34:07.036Z","updated":"2022-09-15T02:34:07.036Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":164,"end":217},{"type":"TextQuoteSelector","exact":"Clinical and Molecular Features and Survival Outcomes","prefix":"matology.orgMast Cell Leukemia: ","suffix":" ofPatients in the ECNM Registry"}]}]}
>```
>%%
>*%%PREFIX%%matology.orgMast Cell Leukemia:%%HIGHLIGHT%% ==Clinical and Molecular Features and Survival Outcomes== %%POSTFIX%%ofPatients in the ECNM Registry*
>%%LINK%%[[#^4pzrdors058|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4pzrdors058


>%%
>```annotation-json
>{"created":"2022-09-15T02:34:32.835Z","updated":"2022-09-15T02:34:32.835Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":16089,"end":16219},{"type":"TextQuoteSelector","exact":"Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis (SM) defined by >20% mast cells (MC) on a bone marrow aspirate","prefix":"st on 14 September 2022Abstract ","suffix":". We evaluated 92 patients with "}]}]}
>```
>%%
>*%%PREFIX%%st on 14 September 2022Abstract%%HIGHLIGHT%% ==Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis (SM) defined by >20% mast cells (MC) on a bone marrow aspirate== %%POSTFIX%%. We evaluated 92 patients with*
>%%LINK%%[[#^637avwk24te|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^637avwk24te


>%%
>```annotation-json
>{"created":"2022-09-15T02:35:12.309Z","updated":"2022-09-15T02:35:12.309Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":17661,"end":17917},{"type":"TextQuoteSelector","exact":"The median OS of MCL patients was 1.58 years; a diagnosis of MCL-AHN and an abnormal karyotype were each associated with inferior outcomes •  Midostaurin was the most commonly used agent in MCL and was associated with improved OS in a multivariate analysis","prefix":"tication of MCL.  Key Points •  ","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%tication of MCL.  Key Points •%%HIGHLIGHT%% ==The median OS of MCL patients was 1.58 years; a diagnosis of MCL-AHN and an abnormal karyotype were each associated with inferior outcomes •  Midostaurin was the most commonly used agent in MCL and was associated with improved OS in a multivariate analysis== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^z68t3dp11zp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^z68t3dp11zp


>%%
>```annotation-json
>{"created":"2022-09-15T02:35:54.884Z","updated":"2022-09-15T02:35:54.884Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":18263,"end":18960},{"type":"TextQuoteSelector","exact":" Non-advanced subtypes of SM include indolent SM (ISM) and smoldering SM (SSM); advanced SM (AdvSM) subtypes include aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL).1-4 MCL is rare, comprising <5% of all SM cases, and is defined by World Health Organization (WHO) diagnostic criteria for SM plus the criterion of ≥ 20% MCs on a BM aspirate smear.5 Although one or more C-findings (SM-related organ damage) is a prerequisite for a diagnosis of ASM, it is not required for a diagnosis of SM-AHN or MCL, despite being commonly encountered in these diseases.  The prognosis of MCL is often grim, with a median overall survival (OS) of < 2 years.5","prefix":"ne marrow (BM) and other organs.","suffix":"-7   MCL can be further subdivid"}]}]}
>```
>%%
>*%%PREFIX%%ne marrow (BM) and other organs.%%HIGHLIGHT%% ==Non-advanced subtypes of SM include indolent SM (ISM) and smoldering SM (SSM); advanced SM (AdvSM) subtypes include aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL).1-4 MCL is rare, comprising <5% of all SM cases, and is defined by World Health Organization (WHO) diagnostic criteria for SM plus the criterion of ≥ 20% MCs on a BM aspirate smear.5 Although one or more C-findings (SM-related organ damage) is a prerequisite for a diagnosis of ASM, it is not required for a diagnosis of SM-AHN or MCL, despite being commonly encountered in these diseases.  The prognosis of MCL is often grim, with a median overall survival (OS) of < 2 years.5== %%POSTFIX%%-7   MCL can be further subdivid*
>%%LINK%%[[#^ryl5z5mew5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ryl5z5mew5


>%%
>```annotation-json
>{"created":"2022-09-15T02:36:15.679Z","updated":"2022-09-15T02:36:15.679Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":18966,"end":19317},{"type":"TextQuoteSelector","exact":"CL can be further subdivided into variants based on clinicopathologic features. These subtypes include: primary (de novo) vs. secondary MCL (arising from another SM variant); acute (with C-findings) vs. chronic (without C-findings) MCL; MCL with or without an AHN; and leukemic (> 10% circulating MC) vs. aleukemic MCL (< 10% circulating MC).4,5,8-12 ","prefix":"rvival (OS) of < 2 years.5-7   M","suffix":"  More recently, cytogenetic and"}]}]}
>```
>%%
>*%%PREFIX%%rvival (OS) of < 2 years.5-7   M%%HIGHLIGHT%% ==CL can be further subdivided into variants based on clinicopathologic features. These subtypes include: primary (de novo) vs. secondary MCL (arising from another SM variant); acute (with C-findings) vs. chronic (without C-findings) MCL; MCL with or without an AHN; and leukemic (> 10% circulating MC) vs. aleukemic MCL (< 10% circulating MC).4,5,8-12== %%POSTFIX%%More recently, cytogenetic and*
>%%LINK%%[[#^isux4mvsry|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^isux4mvsry


>%%
>```annotation-json
>{"created":"2022-09-15T02:38:14.911Z","updated":"2022-09-15T02:38:14.911Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":20101,"end":20679},{"type":"TextQuoteSelector","exact":"istorically, MCL has been treated with cytoreductive chemotherapy, most commonly single agent cladribine (2-CdA), and in some cases multi-agent acute myeloid leukemia (AML)-type induction regimens.5 A possible salvage treatment option for these patients is allogeneic hematopoietic cell transplantation (allo-HCT), especially when a response to 2-CdA and/or chemotherapy is obtained. However, a multicenter, retrospective series reported that MCL patients (n = 12) exhibited worse overall survival (OS) among all AdvSM patients undergoing allo-HCT, with a 3-year OS of only 17%.","prefix":"patients with AdvSM.6,17-21    H","suffix":"22  More recently, KIT-targeting"}]}]}
>```
>%%
>*%%PREFIX%%patients with AdvSM.6,17-21    H%%HIGHLIGHT%% ==istorically, MCL has been treated with cytoreductive chemotherapy, most commonly single agent cladribine (2-CdA), and in some cases multi-agent acute myeloid leukemia (AML)-type induction regimens.5 A possible salvage treatment option for these patients is allogeneic hematopoietic cell transplantation (allo-HCT), especially when a response to 2-CdA and/or chemotherapy is obtained. However, a multicenter, retrospective series reported that MCL patients (n = 12) exhibited worse overall survival (OS) among all AdvSM patients undergoing allo-HCT, with a 3-year OS of only 17%.== %%POSTFIX%%22  More recently, KIT-targeting*
>%%LINK%%[[#^0syp6xqixv9m|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0syp6xqixv9m


>%%
>```annotation-json
>{"created":"2022-09-15T02:38:54.880Z","updated":"2022-09-15T02:38:54.880Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":20683,"end":20796},{"type":"TextQuoteSelector","exact":"More recently, KIT-targeting drugs have demonstrated encouraging activity in patients with AdvSM, including MCL. ","prefix":"ith a 3-year OS of only 17%.22  ","suffix":"Reduction in objective measures "}]}]}
>```
>%%
>*%%PREFIX%%ith a 3-year OS of only 17%.22%%HIGHLIGHT%% ==More recently, KIT-targeting drugs have demonstrated encouraging activity in patients with AdvSM, including MCL.== %%POSTFIX%%Reduction in objective measures*
>%%LINK%%[[#^4fgr7wshhu1|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4fgr7wshhu1


>%%
>```annotation-json
>{"created":"2022-09-15T02:39:24.451Z","updated":"2022-09-15T02:39:24.451Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":21930,"end":22376},{"type":"TextQuoteSelector","exact":"However, many features of this rare disorder remain incompletely understood. In this study, we describe the clinical characteristics, molecular features, current treatment patterns, and survival outcomes of a well-characterized, multi-institutional cohort of patients with MCL from the European Competence Network on Mastocytosis (ECNM) registry. To our knowledge, this is the largest cohort of patients with this rare advanced myeloid neoplasm. ","prefix":" of 13 patients from the US.5-7 ","suffix":"  Methods  ECNM Registry Databas"}]}]}
>```
>%%
>*%%PREFIX%%of 13 patients from the US.5-7%%HIGHLIGHT%% ==However, many features of this rare disorder remain incompletely understood. In this study, we describe the clinical characteristics, molecular features, current treatment patterns, and survival outcomes of a well-characterized, multi-institutional cohort of patients with MCL from the European Competence Network on Mastocytosis (ECNM) registry. To our knowledge, this is the largest cohort of patients with this rare advanced myeloid neoplasm.== %%POSTFIX%%Methods  ECNM Registry Databas*
>%%LINK%%[[#^j2wq73zd3nf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^j2wq73zd3nf


>%%
>```annotation-json
>{"created":"2022-09-15T02:41:32.740Z","updated":"2022-09-15T02:41:32.740Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":23203,"end":23368},{"type":"TextQuoteSelector","exact":"ll  patients  provided written informed consent or, if deceased or inactive at the treating center, were included according to IRB standards at the treating center. ","prefix":"ion  in  the  ECNM  registry,  a","suffix":"  Downloaded from http://ashpubl"}]}]}
>```
>%%
>*%%PREFIX%%ion  in  the  ECNM  registry,  a%%HIGHLIGHT%% ==ll  patients  provided written informed consent or, if deceased or inactive at the treating center, were included according to IRB standards at the treating center.== %%POSTFIX%%Downloaded from http://ashpubl*
>%%LINK%%[[#^9f09i96bygs|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9f09i96bygs


>%%
>```annotation-json
>{"created":"2022-09-15T02:42:08.206Z","updated":"2022-09-15T02:42:08.206Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":23542,"end":24341},{"type":"TextQuoteSelector","exact":"The following parameters were captured for this study: age, sex, date of diagnosis (histology based), diagnosis according to the WHO classification26, any SM diagnoses prior to diagnosis of MCL, laboratory values at time of MCL diagnosis, percentage of MC in BM aspirate smears and blood films, molecular and cytogenetic data, presence of hepatosplenomegaly, weight loss (defined as >10% loss during the last 12 months prior to diagnosis), skeletal involvement of SM (defined as an osteolytic lesion(s) ≥ 2 cm) , treatment courses, and death or last follow-up. The mutation-adjusted risk score (MARS), the global prognostic score for mastocytosis (GPSM), and international prognostic scoring system for mastocytosis (IPSM) for AdvSM prognosis were each calculated from the above relevant variables.1","prefix":"df by guest on 14 September 2022","suffix":"9,21,27  All cytogenetic analysi"}]}]}
>```
>%%
>*%%PREFIX%%df by guest on 14 September 2022%%HIGHLIGHT%% ==The following parameters were captured for this study: age, sex, date of diagnosis (histology based), diagnosis according to the WHO classification26, any SM diagnoses prior to diagnosis of MCL, laboratory values at time of MCL diagnosis, percentage of MC in BM aspirate smears and blood films, molecular and cytogenetic data, presence of hepatosplenomegaly, weight loss (defined as >10% loss during the last 12 months prior to diagnosis), skeletal involvement of SM (defined as an osteolytic lesion(s) ≥ 2 cm) , treatment courses, and death or last follow-up. The mutation-adjusted risk score (MARS), the global prognostic score for mastocytosis (GPSM), and international prognostic scoring system for mastocytosis (IPSM) for AdvSM prognosis were each calculated from the above relevant variables.1== %%POSTFIX%%9,21,27  All cytogenetic analysi*
>%%LINK%%[[#^q35xwgoic|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^q35xwgoic


>%%
>```annotation-json
>{"created":"2022-09-15T02:46:05.499Z","updated":"2022-09-15T02:46:05.499Z","document":{"title":"bloodadvances.2022008292.pdf","link":[{"href":"urn:x-pdf:812d159f04a566fbdbd6ad8744fd36b3"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf"}],"documentFingerprint":"812d159f04a566fbdbd6ad8744fd36b3"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022008292.pdf","selector":[{"type":"TextPositionSelector","start":25719,"end":25817},{"type":"TextQuoteSelector","exact":" Analyses were performed using R 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). ","prefix":".05 were considered significant.","suffix":"  Results Clinical and Laborator"}]}]}
>```
>%%
>*%%PREFIX%%.05 were considered significant.%%HIGHLIGHT%% ==Analyses were performed using R 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria).== %%POSTFIX%%Results Clinical and Laborator*
>%%LINK%%[[#^ic7p5bqo2xs|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ic7p5bqo2xs
